欧林生物：发行境外上市股份（H股）备案申请材料获证监会接收

Core Viewpoint - The company has submitted an application for the public issuance of H-shares and listing on the Hong Kong Stock Exchange, indicating a strategic move to expand its capital base and market presence [1] Group 1 - The company submitted its application on November 25, 2025, to the Hong Kong Stock Exchange for the issuance of H-shares [1] - The application materials for this issuance have been accepted by the China Securities Regulatory Commission [1] - The issuance and listing are subject to approval from relevant regulatory bodies and stock exchanges, indicating potential uncertainties [1]